Cogent Biosciences Company Insiders
| COGT Stock | USD 9.58 0.05 0.52% |
Cogent Biosciences' insiders are aggressively buying. The analysis of the overall insider sentiment regarding Cogent Biosciences suggests that vertually all insiders are extremely bullish. Cogent Biosciences employs about 164 people. The company is managed by 11 executives with a total tenure of roughly 383 years, averaging almost 34.0 years of service per executive, having 14.91 employees per reported executive.
Cogent Biosciences' Insider Buying Vs Selling
100
Selling | Buying |
Latest Trades
| 2023-06-09 | Fairmount Funds Management Llc | Acquired 800000 @ 12 | View | ||
| 2022-06-16 | Fairmount Funds Management Llc | Acquired 1200000 @ 8.25 | View |
Monitoring Cogent Biosciences' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Cogent |
Cogent Biosciences' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Cogent Biosciences' future performance. Based on our forecasts, it is anticipated that Cogent will maintain a workforce of slightly above 160 employees by December 2024.Cogent Biosciences Management Team Effectiveness
The company has return on total asset (ROA) of (0.4402) % which means that it has lost $0.4402 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7847) %, meaning that it created substantial loss on money invested by shareholders. Cogent Biosciences' management efficiency ratios could be used to measure how well Cogent Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.64 in 2024. Return On Capital Employed is likely to drop to -0.79 in 2024. At this time, Cogent Biosciences' Non Current Liabilities Other is comparatively stable compared to the past year. Change To Liabilities is likely to gain to about 14.4 M in 2024, whereas Total Current Liabilities is likely to drop slightly above 21.1 M in 2024.Common Stock Shares Outstanding is likely to gain to about 83.6 M in 2024, whereas Net Loss is likely to drop (132.5 M) in 2024.
Cogent Biosciences Workforce Comparison
Cogent Biosciences is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 3,199. Cogent Biosciences holds roughly 164 in number of employees claiming about 5% of equities under Health Care industry.
Cogent Biosciences Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Cogent Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Cogent Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Cogent Biosciences insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2024-06-01 | 4.5 | 9 | 2 | 2,296,413 | 1,500 |
| 2024-03-01 | 5.5 | 11 | 2 | 3,728,280 | 298,765 |
| 2021-06-01 | 1.5 | 3 | 2 | 264,189 | 35,626 |
| 2021-03-01 | 16.0 | 16 | 1 | 1,647,486 | 500,000 |
| 2020-09-01 | 5.5 | 11 | 2 | 6,622,566 | 141,332 |
| 2020-06-01 | 0.3913 | 9 | 23 | 319,389 | 2,000,000 |
| 2019-09-01 | 1.0 | 5 | 5 | 199,015 | 140,878 |
| 2019-03-01 | 2.4 | 12 | 5 | 409,698 | 55,175 |
| 2018-12-01 | 1.3333 | 8 | 6 | 45,351 | 68,910 |
| 2018-09-01 | 3.0 | 6 | 2 | 19,250 | 22,970 |
| 2018-06-01 | 2.1111 | 19 | 9 | 12,069,479 | 9,336,534 |
| 2018-03-01 | 0.5 | 14 | 28 | 1,650,000 | 7,189,075 |
| 2017-09-01 | 0.3333 | 4 | 12 | 716,667 | 273,540 |
| 2017-06-01 | 7.5 | 15 | 2 | 554,530 | 30,471 |
| 2017-03-01 | 8.0 | 8 | 1 | 409,250 | 54,417 |
| 2016-12-01 | 5.5 | 22 | 4 | 801,407 | 592,500 |
| 2010-12-01 | 0.2857 | 2 | 7 | 8,000 | 1,974,436 |
| 2010-09-01 | 2.0 | 2 | 1 | 8,000 | 3,000,000 |
| 2010-06-01 | 1.0 | 1 | 1 | 40,000 | 2,600,000 |
| 2009-09-01 | 0.75 | 3 | 4 | 18,000 | 1,523,000 |
| 2008-09-01 | 0.8333 | 5 | 6 | 300,000 | 3,033,508 |
| 2008-06-01 | 0.3571 | 45 | 126 | 109,665 | 1,232,290 |
| 2007-12-01 | 1.0 | 3 | 3 | 140,000 | 80,000 |
| 2007-09-01 | 1.0 | 4 | 4 | 61,250 | 102,500 |
| 2007-06-01 | 0.25 | 1 | 4 | 7,500 | 30,000 |
| 2005-12-01 | 0.6 | 3 | 5 | 25,000 | 44,017 |
| 2005-06-01 | 0.3182 | 7 | 22 | 988,056 | 9,232,362 |
| 2005-03-01 | 0.5 | 2 | 4 | 114,479 | 228,958 |
| 2004-09-01 | 0.25 | 1 | 4 | 3,000 | 1,030,000 |
Cogent Biosciences Notable Stakeholders
A Cogent Biosciences stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Cogent Biosciences often face trade-offs trying to please all of them. Cogent Biosciences' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Cogent Biosciences' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Andrew MBA | CEO President | Profile | |
| Rachael MD | VP Development | Profile | |
| Sara Saltzman | VP Affairs | Profile | |
| Jessica MD | Chief Officer | Profile | |
| Brad Fell | Senior Chemistry | Profile | |
| Christi Waarich | Senior Relations | Profile | |
| Brad Barnett | Chief Officer | Profile | |
| Erin Schellhammer | Chief Officer | Profile | |
| John Robinson | Chief Officer | Profile | |
| Evan JD | Chief Secretary | Profile | |
| Dana PharmD | Senior Officer | Profile |
About Cogent Biosciences Management Performance
The success or failure of an entity such as Cogent Biosciences often depends on how effective the management is. Cogent Biosciences management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Cogent management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Cogent management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.61) | (0.64) | |
| Return On Capital Employed | (0.76) | (0.79) | |
| Return On Assets | (0.61) | (0.64) | |
| Return On Equity | (0.75) | (0.78) |
Please note, the imprecision that can be found in Cogent Biosciences' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Cogent Biosciences. Check Cogent Biosciences' Beneish M Score to see the likelihood of Cogent Biosciences' management manipulating its earnings.
Cogent Biosciences Workforce Analysis
Traditionally, organizations such as Cogent Biosciences use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Cogent Biosciences within its industry.Cogent Biosciences Manpower Efficiency
Return on Cogent Biosciences Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 1.2M | |
| Net Loss Per Executive | 17.5M | |
| Working Capital Per Employee | 1.4M | |
| Working Capital Per Executive | 21.1M |
Additional Tools for Cogent Stock Analysis
When running Cogent Biosciences' price analysis, check to measure Cogent Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cogent Biosciences is operating at the current time. Most of Cogent Biosciences' value examination focuses on studying past and present price action to predict the probability of Cogent Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cogent Biosciences' price. Additionally, you may evaluate how the addition of Cogent Biosciences to your portfolios can decrease your overall portfolio volatility.